Replaced platelet concentrates containing a new additive solution, M ‐sol: safety and efficacy for pediatric patients
2012; Wiley; Volume: 53; Issue: 9 Linguagem: Inglês
10.1111/trf.12025
ISSN1537-2995
AutoresRyu Yanagisawa, Shigetaka Shimodaira, Shunsuke Kojima, Nobuhiko Nakasone, Shinsuke Ishikawa, Kayo Momose, Takayuki Honda, Kentaro Yoshikawa, Shoji Saito, Miyuki Tanaka, Yozo Nakazawa, Kazuo Sakashita, Masaaki Shiohara, Mitsuaki Akino, Junichi Hirayama, Hiroshi Azuma, Kenichi Koike,
Tópico(s)Platelet Disorders and Treatments
ResumoBackground Allergic transfusion reactions ( ATR s), particularly those caused by plasma‐rich platelet concentrates ( P ‐ PC s), are an important concern in transfusion medicine. Replacing P ‐ PCs with PCs containing M ‐sol ( M ‐sol‐ R ‐ PC s) is expected to prevent ATR s. However, this has not yet been verified by sufficient clinical evidence. Study Design and Methods A retrospective cohort study was performed between 2008 and 2011. Pediatric patients with hematologic disorders, solid tumors, primary immunodeficiency disorders, or inherited metabolic disorders were transfused with M ‐sol‐ R ‐ PCs between 2010 and 2011; the transfusions of P ‐ PC s administered between 2008 and 2011 were compared in terms of frequency and severity of ATR s, corrected count increment ( CCI ), and occurrence of bleeding. Data were collected for 6 consecutive months on a per‐patient basis. Results Data obtained during 2008 to 2011 showed that of the 78 patients receiving 515 P ‐ PC transfusions, 14 (17.9%) had 17 ATR s (3.3%); 14 and three ATR s were of Grades 1 and 2, respectively. In 2010 to 2011, 49 patients received 620 transfusions of M ‐sol‐R‐ PCs , and two patients (4.1%) had Grade 1 ATR s (0.3%). Thus, the frequency of ATR s per bag and per patient differed significantly between the two transfusions. No steroid agents were used for the prevention or treatment of ATR s in the M ‐sol‐ R ‐ PC group. The CCI (24 hr) for M ‐sol‐ R ‐ PCs did not differ from that for P ‐ PCs . Conclusion M ‐sol‐ R ‐ PCs were found to be effective in preventing ATR s without loss of transfusion efficiency in children; however, its efficacy should be further evaluated in prospective clinical trials.
Referência(s)